Table 4.
Regression modeling results for echocardiographic measurements, stratified by serum BNP
| Echocardiographic measurements | BNP ≥100 pg/ml
|
BNP <100 pg/ml
|
p* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Coefficient | 95% CI | p | n | Coefficient | 95% CI | p | n | ||
| Ventricular inflow | |||||||||
| E velocity (cm/s) | 5.6 | (−2.9, 14) | 0.19 | 12 | 4.7 | (−3.4, 13) | 0.24 | 15 | 0.88 |
| A velocity (cm/s) | 0.63 | (−4.2, 5.4) | 0.79 | 10 | 0.88 | (−2.9, 4.7) | 0.64 | 15 | 0.93 |
| Tissue Doppler | |||||||||
| S′ velocity (cm/s) | 0.54 | (−0.20, 1.3) | 0.14 | 11 | −0.084 | (−0.80, 0.64) | 0.81 | 14 | 0.25 |
| E′ velocity (cm/s) | 0.21 | (−1.6, 2.1) | 0.82 | 11 | 0.27 | (−1.4, 1.9) | 0.73 | 14 | 0.96 |
| A′ velocity (cm/s) | 0.032 | (−0.96, 1.0) | 0.95 | 9 | –0.35 | (−1.2, 0.50) | 0.40 | 14 | 0.56 |
| Diastolic performance | |||||||||
| E velocity/A velocity | −0.0047 | (−0.28, 0.27) | 0.97 | 10 | 0.07 | (−0.14, 0.28) | 0.50 | 15 | 0.67 |
| E velocity/E′ velocity | 0.82 | (−1.2, 2.9) | 0.42 | 11 | 0.48 | (−1.4, 2.4) | 0.60 | 14 | 0.82 |
| Systolic performance | |||||||||
| VTI × HR (cm × bpm) | 190 | (31, 340) | 0.02 | 11 | 58 | (−78, 190) | 0.38 | 15 | 0.21 |
| VTI (cm) | 1.3 | (−0.67, 3.2) | 0.19 | 12 | 1.0 | (−0.77, 2.8) | 0.25 | 15 | 0.87 |
| Heart rate (bpm) | 4.2 | (−2.7, 11) | 0.22 | 11 | 0.33 | (−5.6, 6.3) | 0.91 | 15 | 0.39 |
| Global ventricular performance | |||||||||
| MPI | −0.076 | (−0.15, -0.0043) | 0.04 | 11 | −0.034 | (−0.091, 0.023) | 0.23 | 15 | 0.35 |
a
Data are presented as coefficient, 95% CI, and p value. Each regression coefficient corresponds to the difference in the average post-phase outcome between sildenafil and placebo adjusted for pre-phase values, study period, and treatment sequence
*
p-value from test of interaction evaluating whether the treatment difference is equal in the two BNP strata
n number of subjects with a complete measurement series